Yahoo
NasdaqCM - Delayed Quote USD

vTv Therapeutics Inc. (VTVT)

33.35 -0.12 (-0.36%)
At close: September 4 at 4:00:00 PM EDT
33.35 0.00 (0.00%)
After hours: September 4 at 7:30:02 PM EDT
Trade VTVT on Coinbase
Chart Range Bar
Loading chart for VTVT
  • Previous Close 33.47
  • Open 33.30
  • Bid 31.50 x 300
  • Ask 32.80 x 100
  • Day's Range 33.17 - 33.72
  • 52 Week Range 18.76 - 44.00
  • Volume 12,064
  • Avg. Volume 74,611
  • Market Cap (intraday) 131.863M
  • Beta (5Y Monthly) 0.28
  • PE Ratio (TTM) --
  • EPS (TTM) -0.75
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 54.71

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.

vtvtherapeutics.com

26

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

VTVT
16.60%
S&P 500 (^GSPC)
12.75%

1-Year Return

VTVT
79.88%
S&P 500 (^GSPC)
18.71%

3-Year Return

VTVT
63.48%
S&P 500 (^GSPC)
70.93%

5-Year Return

VTVT
55.17%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -13.05M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-10M
0
10M
20M
30M
0.0%
20.0%
40.0%
60.0%

Analyst Insights

View More

Analyst Price Targets

42.00
54.71 Average
33.35 Current
67.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/6/2026
Analyst HC Wainwright & Co.
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 45 -> 42

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -12.91%

  • Return on Assets (ttm)

    -10.14%

  • Return on Equity (ttm)

    -15.80%

  • Revenue (ttm)

    36.84M

  • Net Income Avi to Common (ttm)

    -4.76M

  • Diluted EPS (ttm)

    -0.75

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    86.64M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    674.38k

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: